Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels

Neil Ruparelia, Nicola Buzzatti, Vittorio Romano, Matteo Longoni, Fillipo Figini, Matteo Montorfano, Hiroyoshi Kawamoto, Tadashi Miyazaki, Pietro Spagnolo, Ottavio Alfieri, Antonio Colombo, Azeem Latib

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: The aim of this study was to assess the feasibility, safety and short-term outcomes of transfemoral transcatheter aortic valve implantation (TF-TAVI) in patients with small diseased peripheral vessels. Background: The transfemoral (TF) route for transcatheter aortic valve (TAVI) is the default option due to associated advantages. However, this is limited due to the high prevalence of significant peripheral arterial disease and increased risk of vascular complications. Methods: Of 539 consecutive patients undergoing TAVI in a single Italian center, 23 patients underwent TF-TAVI in the presence of small peripheral vessels as defined by a minimal luminal diameter (MLD) of ≤ 5.5. mm [by computed tomography (CT)] and/or the inability to advance a large-bore sheath. Calcification was defined as being concentric if calcium extended more than 270° around the circumference of the artery. All patients underwent 30-day clinical follow-up. Results: 17 (73.9%) patients underwent peripheral vessel pre-dilatation with a semi-compliant balloon and 6 (26.1%) patients with a Solopath sheath. 6 (26.1%) patients suffered a peri-procedural complication, with 1 patient requiring surgical embolectomy for thrombotic occlusion and the remaining patients successfully managed percutaneously in the catheter laboratory. No patient suffered a vessel perforation or required implantation of a covered stent. At 30-day follow-up, all patients were free of symptoms and signs or symptoms of peripheral vascular disease, with well-functioning TAVI prostheses as evaluated by echocardiography. Conclusions: Performing TF-TAVI is feasible in patients with no other viable vascular access option in the presence of small MLD and calcification of the peripheral vasculature, with any anticipated acute vascular complication managed in the catheter laboratory with established percutaneous techniques.

Original languageEnglish
Pages (from-to)326-330
Number of pages5
JournalCardiovascular Revascularization Medicine
Volume16
Issue number6
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Blood Vessels
Transcatheter Aortic Valve Replacement
Catheters
Embolectomy
Peripheral Vascular Diseases
Peripheral Arterial Disease
Aortic Valve
Signs and Symptoms
Prostheses and Implants
Stents
Echocardiography
Dilatation
Arteries
Tomography
Calcium
Safety

Keywords

  • Peripheral access
  • TAVI
  • Transcatheter aortic valve implantation
  • Vascular access

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels. / Ruparelia, Neil; Buzzatti, Nicola; Romano, Vittorio; Longoni, Matteo; Figini, Fillipo; Montorfano, Matteo; Kawamoto, Hiroyoshi; Miyazaki, Tadashi; Spagnolo, Pietro; Alfieri, Ottavio; Colombo, Antonio; Latib, Azeem.

In: Cardiovascular Revascularization Medicine, Vol. 16, No. 6, 01.09.2015, p. 326-330.

Research output: Contribution to journalArticle

Ruparelia, N, Buzzatti, N, Romano, V, Longoni, M, Figini, F, Montorfano, M, Kawamoto, H, Miyazaki, T, Spagnolo, P, Alfieri, O, Colombo, A & Latib, A 2015, 'Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels', Cardiovascular Revascularization Medicine, vol. 16, no. 6, pp. 326-330. https://doi.org/10.1016/j.carrev.2015.05.013
Ruparelia, Neil ; Buzzatti, Nicola ; Romano, Vittorio ; Longoni, Matteo ; Figini, Fillipo ; Montorfano, Matteo ; Kawamoto, Hiroyoshi ; Miyazaki, Tadashi ; Spagnolo, Pietro ; Alfieri, Ottavio ; Colombo, Antonio ; Latib, Azeem. / Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels. In: Cardiovascular Revascularization Medicine. 2015 ; Vol. 16, No. 6. pp. 326-330.
@article{4ba95a60dbb04a1c8f40fddb4d69129e,
title = "Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels",
abstract = "Objectives: The aim of this study was to assess the feasibility, safety and short-term outcomes of transfemoral transcatheter aortic valve implantation (TF-TAVI) in patients with small diseased peripheral vessels. Background: The transfemoral (TF) route for transcatheter aortic valve (TAVI) is the default option due to associated advantages. However, this is limited due to the high prevalence of significant peripheral arterial disease and increased risk of vascular complications. Methods: Of 539 consecutive patients undergoing TAVI in a single Italian center, 23 patients underwent TF-TAVI in the presence of small peripheral vessels as defined by a minimal luminal diameter (MLD) of ≤ 5.5. mm [by computed tomography (CT)] and/or the inability to advance a large-bore sheath. Calcification was defined as being concentric if calcium extended more than 270° around the circumference of the artery. All patients underwent 30-day clinical follow-up. Results: 17 (73.9{\%}) patients underwent peripheral vessel pre-dilatation with a semi-compliant balloon and 6 (26.1{\%}) patients with a Solopath sheath. 6 (26.1{\%}) patients suffered a peri-procedural complication, with 1 patient requiring surgical embolectomy for thrombotic occlusion and the remaining patients successfully managed percutaneously in the catheter laboratory. No patient suffered a vessel perforation or required implantation of a covered stent. At 30-day follow-up, all patients were free of symptoms and signs or symptoms of peripheral vascular disease, with well-functioning TAVI prostheses as evaluated by echocardiography. Conclusions: Performing TF-TAVI is feasible in patients with no other viable vascular access option in the presence of small MLD and calcification of the peripheral vasculature, with any anticipated acute vascular complication managed in the catheter laboratory with established percutaneous techniques.",
keywords = "Peripheral access, TAVI, Transcatheter aortic valve implantation, Vascular access",
author = "Neil Ruparelia and Nicola Buzzatti and Vittorio Romano and Matteo Longoni and Fillipo Figini and Matteo Montorfano and Hiroyoshi Kawamoto and Tadashi Miyazaki and Pietro Spagnolo and Ottavio Alfieri and Antonio Colombo and Azeem Latib",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.carrev.2015.05.013",
language = "English",
volume = "16",
pages = "326--330",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels

AU - Ruparelia, Neil

AU - Buzzatti, Nicola

AU - Romano, Vittorio

AU - Longoni, Matteo

AU - Figini, Fillipo

AU - Montorfano, Matteo

AU - Kawamoto, Hiroyoshi

AU - Miyazaki, Tadashi

AU - Spagnolo, Pietro

AU - Alfieri, Ottavio

AU - Colombo, Antonio

AU - Latib, Azeem

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objectives: The aim of this study was to assess the feasibility, safety and short-term outcomes of transfemoral transcatheter aortic valve implantation (TF-TAVI) in patients with small diseased peripheral vessels. Background: The transfemoral (TF) route for transcatheter aortic valve (TAVI) is the default option due to associated advantages. However, this is limited due to the high prevalence of significant peripheral arterial disease and increased risk of vascular complications. Methods: Of 539 consecutive patients undergoing TAVI in a single Italian center, 23 patients underwent TF-TAVI in the presence of small peripheral vessels as defined by a minimal luminal diameter (MLD) of ≤ 5.5. mm [by computed tomography (CT)] and/or the inability to advance a large-bore sheath. Calcification was defined as being concentric if calcium extended more than 270° around the circumference of the artery. All patients underwent 30-day clinical follow-up. Results: 17 (73.9%) patients underwent peripheral vessel pre-dilatation with a semi-compliant balloon and 6 (26.1%) patients with a Solopath sheath. 6 (26.1%) patients suffered a peri-procedural complication, with 1 patient requiring surgical embolectomy for thrombotic occlusion and the remaining patients successfully managed percutaneously in the catheter laboratory. No patient suffered a vessel perforation or required implantation of a covered stent. At 30-day follow-up, all patients were free of symptoms and signs or symptoms of peripheral vascular disease, with well-functioning TAVI prostheses as evaluated by echocardiography. Conclusions: Performing TF-TAVI is feasible in patients with no other viable vascular access option in the presence of small MLD and calcification of the peripheral vasculature, with any anticipated acute vascular complication managed in the catheter laboratory with established percutaneous techniques.

AB - Objectives: The aim of this study was to assess the feasibility, safety and short-term outcomes of transfemoral transcatheter aortic valve implantation (TF-TAVI) in patients with small diseased peripheral vessels. Background: The transfemoral (TF) route for transcatheter aortic valve (TAVI) is the default option due to associated advantages. However, this is limited due to the high prevalence of significant peripheral arterial disease and increased risk of vascular complications. Methods: Of 539 consecutive patients undergoing TAVI in a single Italian center, 23 patients underwent TF-TAVI in the presence of small peripheral vessels as defined by a minimal luminal diameter (MLD) of ≤ 5.5. mm [by computed tomography (CT)] and/or the inability to advance a large-bore sheath. Calcification was defined as being concentric if calcium extended more than 270° around the circumference of the artery. All patients underwent 30-day clinical follow-up. Results: 17 (73.9%) patients underwent peripheral vessel pre-dilatation with a semi-compliant balloon and 6 (26.1%) patients with a Solopath sheath. 6 (26.1%) patients suffered a peri-procedural complication, with 1 patient requiring surgical embolectomy for thrombotic occlusion and the remaining patients successfully managed percutaneously in the catheter laboratory. No patient suffered a vessel perforation or required implantation of a covered stent. At 30-day follow-up, all patients were free of symptoms and signs or symptoms of peripheral vascular disease, with well-functioning TAVI prostheses as evaluated by echocardiography. Conclusions: Performing TF-TAVI is feasible in patients with no other viable vascular access option in the presence of small MLD and calcification of the peripheral vasculature, with any anticipated acute vascular complication managed in the catheter laboratory with established percutaneous techniques.

KW - Peripheral access

KW - TAVI

KW - Transcatheter aortic valve implantation

KW - Vascular access

UR - http://www.scopus.com/inward/record.url?scp=84941874973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941874973&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2015.05.013

DO - 10.1016/j.carrev.2015.05.013

M3 - Article

C2 - 26104848

AN - SCOPUS:84941874973

VL - 16

SP - 326

EP - 330

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 6

ER -